Lignospan (Epinephrine, Anhydrous Lidocaine Hydrochloride)

Lignospan is a local anesthetic solution used in dental practice to manage pain and facilitate procedures.

• Dental procedures requiring local anesthesia: provides numbness of the targeted area to allow painless treatment.
• Management of acute dental pain: rapidly reduces pain associated with dental trauma or infection.
• Pulpitis: alleviates inflammation‑related discomfort during endodontic therapy.

• Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of nerve impulses. Epinephrine activates alpha‑adrenergic receptors on vascular smooth muscle, causing vasoconstriction that reduces local blood flow, limits systemic absorption of lidocaine, and prolongs its anesthetic effect during dental procedures.

Adverse reactions may occur following administration of Lignospan.

Common Side Effects

• Transient burning or stinging at the injection site.
• Tingling or mild numbness that persists briefly after the procedure.
• Localized swelling or bruising.
• Headache or light‑headedness.
• Dizziness.
• Mild increase in heart rate.

Serious or Rare Side Effects

• Allergic reaction including rash, itching, or anaphylaxis.
• Significant hypertension or tachycardia.
• Cardiac arrhythmias or myocardial ischemia.
• Seizures due to excessive lidocaine levels.
• Prolonged or profound numbness affecting speech or swallowing.
• Severe hypotension.

Prior to using Lignospan, clinicians should consider several safety measures.

• Allergy assessment: verify no known hypersensitivity to lidocaine, epinephrine or related compounds.
• Cardiovascular caution: avoid or use with extreme care in patients with uncontrolled hypertension, arrhythmias or severe coronary disease.
• Beta‑blocker interaction: monitor for altered heart‑rate responses when patients are on non‑selective beta‑blockers.
• Drug‑interaction review: assess concurrent use of MAO inhibitors or other sympathomimetics.
• Aseptic technique: ensure sterile handling to prevent infection at the injection site.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Lignospan may interact with other medications; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• MAO inhibitors: combined use with epinephrine can precipitate hypertensive crisis.
• Non‑selective beta‑blockers: may mask epinephrine‑induced tachycardia and increase blood pressure.
• Tricyclic antidepressants: can potentiate lidocaine toxicity, leading to CNS effects.
• Class I antiarrhythmics (e.g., quinidine): increase risk of cardiac conduction disturbances.
• Monoamine oxidase inhibitors: heightened risk of severe hypertension.

Moderate Interactions (Monitor Closely)

• Other local anesthetics: cumulative lidocaine exposure may raise toxicity risk.
• CYP450 inhibitors (e.g., cimetidine, fluoroquinolones): may slow lidocaine metabolism.
• Sympathomimetic drugs (e.g., phenylephrine): additive vasoconstrictive effects.
• Diuretics: may alter plasma electrolyte balance affecting lidocaine action.
• Antihypertensive agents: monitor blood pressure for additive effects.